Advertisement

Topics

Dutch and German Biotechs enter the Clinic with their First Lanthipeptide

08:40 EST 21 Feb 2017 | Labiotech.eu

Lanthio Pharma has initiated a Phase I clinical trial with its lanthipeptide candidate MOR107, which is being developed as a therapy for diabetic nephropathy. Lanthio Pharma, a Dutch subsidiary of the big German antibody biotech MorphoSys, has initiated its first ...

This awesome article Dutch and German Biotechs enter the Clinic with their First Lanthipeptide appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Dutch and German Biotechs enter the Clinic with their First Lanthipeptide

NEXT ARTICLE

More From BioPortfolio on "Dutch and German Biotechs enter the Clinic with their First Lanthipeptide"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...